喀什地区鸡大肠杆菌的分离鉴定及多价灭活苗的研制

鸡大肠杆菌病是由大肠埃希氏杆菌的某些血清型所引起的鸡的一类传染病的总称。喀什地区 ,该病的流行随规模化养鸡业的发展不断蔓延。据初步调查 ,目前发病率达 3 0 %,每年因该病死亡鸡达 5万余只 ,造成很大的经济损失。为寻找一种经济有效的防制方法 ,自 1 998年以来 ,我们从喀     

Protection of chickens after live and inactivated virus vaccination against challenge with nephropathogenic infectious bronchitis virus PA/Wolgemuth/98

Protection provided by live and inactivated virus vaccination against challenge with the virulent nephropathogenic infectious bronchitis virus (NIBV) strain PA/Wolgemuth/98 was assessed. Vaccinations with combinations of live attenuated strains Massachusetts (Mass) + Connecticut (Conn) or Mass + Arkansas (Ark) were given by eyedrop to 2-wk-old specific-pathogen-free leghorn chickens. After live infectious bronchitis virus (IBV) vaccination, some chickens at 6 wk of age received an injection of either an oil emulsion vaccine containing inactivated IBV strains Mass + Ark or an autogenous vaccine prepared from NIBV PA/Wolgemuth/98. Challenge with PA/Wolgemuth/98 was given via eyedrop at 10 wk of age. Serum IBV enzyme-linked immunosorbent assay antibody geometric mean titers (GMTs) after vaccination with the combinations of live attenuated strains were low, ranging from 184 to 1,354, prior to NIBV challenge at 10 wk of age. Both inactivated vaccines induced an anamnestic response of similar magnitudes with serum GMTs of 6,232-12,241. Assessment of protection following NIBV challenge was based on several criteria virus reisolation from trachea and kidney and renal microscopic pathology and IBV-specific antigen immunohistochemistry (IHC). Live attenuated virus vaccination alone with combinations of strains Mass + Conn or Mass + Ark did not protect the respiratory tract and kidney of chickens after PA/Wolgemuth/98 challenge. Chickens given a live combination vaccination of Mass + Conn and boosted with an inactivated Mass + Ark vaccine were also susceptible to NIBV challenge on the basis of virus isolation from trachea and kidney butshowed protection on the basis of renal microscopic pathology and IHC. Live IBV-primed chickens vaccinated with an autogenous inactivated PA/Wolgemuth/98 vaccine had the highest protection against homologous virulent NIBV challenge on the basis of virus isolation.     

牛传染性鼻气管炎病毒LN01/08株灭活疫苗的研制

为研制牛传染性鼻气管炎病毒(IBRV)灭活疫苗,本研究以国内分离鉴定的IBRV LN01/08株为种毒,优化病毒增殖条件,获得病毒滴度达108.0TCID50/mL,将其灭活制备疫苗.为比较不同免疫佐剂的效果,分别以矿物质白油和Montanide ISA206佐剂配制灭活疫苗,进行牛体免疫试验.临床观察和血清中和抗体检测结果表明,Montanide ISA206佐剂乳化的疫苗在降低副反应和增强免疫效果方面优于矿物质白油佐剂.应用Montanide ISA206佐剂制备3批灭活疫苗,并对其安全性和免疫保护效果进行测定.结果表明该疫苗安全可靠,对强毒攻击可产生较好的抵抗力,攻毒保护率达80%.疫苗在2℃～8℃保存12个月后仍能保持良好的免疫效果.     

Identification of a mimotope of an infectious bronchitis virus S1 protein

The S1 protein of the infectious bronchitis virus (IBV) is a major structural protein that induces the production of the virus-neutralization antibodies. The monoclonal antibody against the IBV M41 S1 protein was used as a target for biopanning. After three rounds of biopanning, randomly selected phages bound to the monoclonal antibody. Sequence analysis showed that the dominant sequence was SFYDFEMQGFFI. Indirect competitive enzyme-linked immunosorbent assay showed that SFYDFEMQGFFI is a mimotope of the S1 protein that was predicted by PepSurf. The mimotope may provide information for further structural and functional analyses of the S1 protein.     

Protection conferred by a vaccine derived from an inactivated Egyptian variant of infectious bronchitis virus: a challenge experiment

Tropical Animal Health and Production - The current study investigated the protective efficacy of a formalin-inactivated infectious bronchitis virus (IBV) vaccine derived from the field strain...     

Protection of laying hens against infectious bronchitis with inactivated emulsion vaccines

Commercially-reared laying chickens were challenged at 31 weeks of age with a virulent infectious bronchitis (IB) virus. They showed a sharp drop in egg production, despite having been vaccinated at four and eight weeks old with live attenuated IB vaccines to a recommended schedule. In contrast, similar birds that had been further immunised at point-of-lay with inactivated oil emulsion IB vaccine, or with a combined IB/Newcastle disease (ND) emulsion vaccine, showed no detectable fall in egg production after the same challenge. Unvaccinated susceptible specific pathogen-free birds challenged at the same time stopped laying almost completely. In the birds revaccinated with emulsion vaccine, measurement of haemagglutination inhibition antibody levels to IB showed their geometric mean titres to be raised from less than 5 log2 at the time of vaccination to over 10 log2 four weeks later. Their antibody levels did not rise further followining the IB challenge whereas in the birds that had not been revaccinated antibody rises to nearly 10 log2 were detected after the same challenge. For pullets vaccinated earlier with live IB vaccine, revaccination with inactivated IB or IB/ND oil emulsion vaccine at point-of-lay provides a safe and effective way of protecting their egg production against IB infection.     

鸡轮状病毒灭活油乳疫苗的制备与应用研究

利用从发生流行性腹泻的发病鸡中分离的轮状病毒,研制了鸡轮状病毒灭活油乳疫苗,并对该疫苗的安全性及免疫效果进行了测定.结果表明该疫苗安全可靠,注射后对增重、产蛋均无影响.免疫后14 d攻毒保护率可达98%以上,免疫期可维持6个月,4℃保存12个月,10℃～25℃保存3个月,免疫效果不变.对鸡轮状病毒油乳灭活疫苗在山东不同地区进行田间试验和扩大区域试验,结果表明该疫苗性能良好、安全,对蛋鸡、肉鸡、雏鸡的生产性能无明显影响,疫苗接种后保护率可达92%以上,可有效地控制该病的发生.     

鸡新城疫-鸡传染性支气管炎-禽流感-产蛋下降综合征四联灭活油乳剂疫苗的研制与免疫试验

用鸡新城疫La Sota株,鸡传染性支气管炎H120株,产蛋下降综合征127株和禽流感病毒HB1(H9N2)株做为抗原制成油乳剂灭活联苗,并对其进行了物理性状、纯净、安全性、灭活效果、保存期和免疫效力等方面的检验.证明所制备疫苗完全符合质量标准;鸡体对该疫苗4种抗原均产生了良好的免疫应答;攻毒试验证明,免疫鸡能良好地抵抗同种强毒的攻击;所制备疫苗于2～8℃保存12个月后,其免疫效力没有下降.     

Cell mediated and humoral immune response of chickens to inactivated oil-emulsion infectious bronchitis vaccine

A lymphocyte transformation microassay was used to study cell mediated immunity (CMI) in chickens following primary and secondary vaccination with inactivated oil emulsion infectious bronchitis (IB) vaccine and subsequent challenge with Massachusetts-41 (M-41). Humoral immunity was monitored for comparison, using the haemagglutination inhibition (HI) microassay. Positive stimulation indices (2 to 2.7 after primary and 2 to 4.8 after secondary vaccination) were lower and HI titres were higher than those previously reported following primary and secondary vaccination with live IB vaccines. The highest HI titres appeared in birds which had received the inactivated vaccine as a secondary vaccination. Challenge of vaccinated and revaccinated birds resulted in strong HI and weak CMI secondary responses. There was no correlation between CMI and HI antibody production. Monitoring egg production and clinical signs showed that a high level of protection against challenge resulted from revaccination with an inactivated oil adjuvant vaccine.     

Immunogenicity and efficacy of a bivalent vaccine against infectious bronchitis virus

Infectious bronchitis (IB) is a highly contagious viral disease and is responsible for considerable economic losses in the poultry industry, worldwide. To mitigate the IB-associated losses, multiple vaccines are being applied in the sector with variable successes and thus necessitating the development of a potent vaccine to protect against the IB in the poultry. In the present study, we investigated a bivalent live attenuated vaccine consisting of IB virus (IBV) strain H120 (GI-1 lineage) and D274 (GI-12 lineage) to evaluate its protection against heterologous variant of IBV (GI-23 lineage) in chicken. Protection efficacy was evaluated based on the serology, clinical signs, survival rates, tracheal and kidney histopathology and the viral shedding. Results demonstrated that administering live H120 and D274 (named here Classivar®) vaccine in one day-old and 14 days-old provided 100 % protection. We observed a significant increase in the mean antibody titers, reduced virus shedding, and ameliorated histopathology lesions compared to routinely used vaccination regimes. These results revealed that usage of different IBV vaccines combination can successfully ameliorate the clinical outcome and pathology in vaccinated chicks especially after booster vaccination regime using Classivar®. In conclusions, our data indicate that Classivar® vaccine is safe in chicks and may serve as an effective vaccine against the threat posed by commonly circulating IBV strains in the poultry industry.     

Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes

The present study describes the development of DNA vaccines using the hemagglutinin-neuraminidase (HN) and fusion (F) genes from AF2240 Newcastle disease virus strain, namely pIRES/HN, pIRES/F and pIRES-F/HN. Transient expression analysis of the constructs in Vero cells revealed the successful expression of gene inserts in vitro. Moreover, in vivo experiments showed that single vaccination with the constructed plasmid DNA (pDNA) followed by a boost with inactivated vaccine induced a significant difference in enzyme-linked immunosorbent assay antibody levels (p < 0.05) elicited by either pIRES/F, pIRES/F+ pIRES/HN or pIRES-F/HN at one week after the booster in specific pathogen free chickens when compared with the inactivated vaccine alone. Taken together, these results indicated that recombinant pDNA could be used to increase the efficacy of the inactivated vaccine immunization procedure.     

柔嫩艾美耳球虫BJ株核酸疫苗的构建及其免疫保护效果研究

将 E.tenella BJ株的保护性抗原基因 TA4插入真核表达载体中 ,然后在其上游融合方式插入 Et1A基因 ,构建成核酸疫苗并进行体外表达。IFAT检测表明 ,p CT转染细胞的荧光亮度高 ,p CTE载体大 ,转染效率低 ,荧光较弱。动物保护性试验中 ,间隔一周两次免疫鸡后攻虫发现 ,核酸疫苗对球虫感染具有明显的保护作用 ,可显著减轻球虫感染引起的机体增重下降 ,其中 ,重组干扰素联合 p CT中剂量 (5 0 μg)免疫时 ,鸡的增重效果最为明显 ,盲肠病变值也最小 ,ACI可达 16 7.2。试验还发现 ,5 0 μgp CTE可达到 10 0 μg p CT的抗球虫效果 ,ACI在 16 0以上 ,说明融合插入两种基因构建的核酸疫苗对球虫感染的保护效果更佳     

Rapid onset of protection against infectious bovine rhinotracheitis with a modified-live virus multivalent vaccine

This study provides evidence that subcutaneous vaccination of cattle with a commercially available modified-live virus combination vaccine can help reduce clinical signs associated with infectious bovine rhinotracheitis infections in feedlot animals vaccinated at the time of arrival. Calves vaccinated 72 or 96 hours before challenge had reduced clinical signs, lower body temperatures, lower virus titers, and 39% to 76% greater weight gains compared with nonvaccinated controls.     

鸡传染性支气管炎弱毒疫苗株安全性和免疫效力初步评价

通过对QX基因型IBV分离株SDZB0808进行鸡胚连续100次传代致弱后获得子代病毒P100。为了明确P100的的致弱效果和免疫原性,对其进行了安全性和免疫效力评价。安全性试验结果显示,P100以105.5 EID50/只的剂量对3日龄的SPF鸡进行免疫后试验,与正常对照组相比没有明显临床症状和病理变化,气管和肾脏组织也没有病理组织损伤。免疫效力试验结果发现,P100以104.5 EID50/只的剂量免疫3日龄SPF鸡,14d后对同源强毒SDZB0808和异源强毒SDIB821/2012的攻击都具有100%的临床保护,病理组织学检查发现P100免疫攻毒组试验鸡气管和肾脏与正常对照没有差异,排毒检测结果显示P100免疫攻毒组试验鸡内脏组织病毒检出率大大低于攻毒对照组。本研究结果表明P100对SPF鸡具有良好的安全性和免疫效力,可以作为IBV弱毒疫苗候选株。